Clinical Trial Update: A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial evaluating nicotinamide riboside supplementation in early Parkinson disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Nicotinamide Riboside (nicotinamide riboside)

Snippet

Sponsor: Haukeland University Hospital | Conditions: Parkinson Disease | Phase 3 | Status: COMPLETED